For example, our data support current clinical trials and ongoing studies to treat NOTCH1-dependant T-ALL by repurposing FDA-approved HDAC inhibitor drugs, including Vorinostat, Romidepsin, Belinostat, and Panobinostat, which specifically target HDAC1 together with one or more other HDACs (57, 58). This evidence concerns the gene HDAC9 and acute lymphoblastic leukemia.